Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Cash Flow Statement
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Gilead Sciences Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)
Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
| Balance sheet item | Description | The company |
|---|---|---|
| Current liabilities | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | Gilead Sciences Inc. current liabilities as a percentage of total liabilities and stockholders’ equity increased from Q4 2023 to Q1 2024 but then slightly decreased from Q1 2024 to Q2 2024 not reaching Q4 2023 level. |
| Long-term liabilities | Amount of obligation due after one year or beyond the normal operating cycle, if longer. | Gilead Sciences Inc. long-term liabilities as a percentage of total liabilities and stockholders’ equity increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024. |
| Total liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | Gilead Sciences Inc. total liabilities as a percentage of total liabilities and stockholders’ equity increased from Q4 2023 to Q1 2024 but then slightly decreased from Q1 2024 to Q2 2024 not reaching Q4 2023 level. |
| Total Gilead stockholders’ equity | Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | Gilead Sciences Inc. total Gilead stockholders’ equity as a percentage of total liabilities and stockholders’ equity decreased from Q4 2023 to Q1 2024 but then increased from Q1 2024 to Q2 2024 not reaching Q4 2023 level. |